RESUMEN
BACKGROUND AND STUDY AIMS: Percutaneous endoscopic gastrostomy is the most common therapeutic procedure performed by the digestive endoscopists in the upper gastrointestinal tract. It aims to feed patients presenting denutrition and/or insufficient oral intake. Percutaneous endoscopic gastrostomy feasibility is about 95-100 % although in some cases it is impossible to achieve it, leading to ask for a surgical placement. Even though the feasibility of the surgical approach is excellent its complications are quite higher than percutaneous endoscopic placement, it requires general anesthesia and sometimes these patients could be non elligible for it due to their comorbidities (malnutrition, cardio-vascular diseases etc.). Another alternative technique is the percutaneous radiological gastrostomy but this procedure is rarely available in our country. PATIENTS AND METHODS: We described four cases in patients with previous failure of PEG, in which we used an hybrid approach between radiological and endoscopic techniques, allowing the placement of gastrostomy tube, without general anesthesia. RESULTS: This was successful in all patients and there was no complication related to the procedure. CONCLUSIONS: This technique offers an additionnal opportunity to avoid general anesthesia and surgical complications in patients with unfavorable conditions.
Asunto(s)
Endoscopía Gastrointestinal/efectos adversos , Nutrición Enteral/efectos adversos , Fluoroscopía , Gastrostomía/métodos , Gastrostomía/efectos adversos , Humanos , Resultado del TratamientoRESUMEN
We analyzed the rates of antimicrobial resistance of Helicobacter pylori strains isolated from patients from 1990 to 2009 and identified risk factors associated with resistance. Gastric biopsy specimens were collected from several digestive disease centers in Brussels, Belgium. We routinely performed antimicrobial susceptibility testing for clarithromycin (CLR), metronidazole, amoxicillin, tetracycline, and ciprofloxacin. Evaluable susceptibility testing was obtained for 9,430 strains isolated from patients who were not previously treated for Helicobacter pylori infection (1,527 isolates from children and 7,903 from adults) and 1,371 strains from patients who were previously treated (162 isolates from children and 1,209 from adults). No resistance to amoxicillin was observed, and tetracycline resistance was very rare (<0.01%). Primary metronidazole resistance remained stable over the years, with significantly lower rates for isolates from children (23.4%) than for isolates from adults (30.6%). Ciprofloxacin resistance remained rare in children, while it increased significantly over the last years in adults. Primary clarithromycin resistance increased significantly, reaching peaks in 2000 for children (16.9%) and in 2003 for adults (23.7%). A subsequent decrease of resistance rates down to 10% in both groups corresponded to a parallel decrease in macrolide consumption during the same period. Multivariate logistic regression revealed that female gender, age of the patient of 40 to 64 years, ethnic background, the number of previously unsuccessful eradication attempts, and the different time periods studied were independent risk factors of resistance to clarithromycin, metronidazole, and ciprofloxacin. Our study highlights the need to update local epidemiological data. Thus, the empirical CLR-based triple therapy proposed by the Maastricht III consensus report remains currently applicable to our population.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Infecciones por Helicobacter/microbiología , Helicobacter pylori/efectos de los fármacos , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Bélgica , Biopsia , Niño , Preescolar , Femenino , Mucosa Gástrica/microbiología , Helicobacter pylori/aislamiento & purificación , Humanos , Lactante , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Factores Sexuales , Adulto JovenRESUMEN
The prevalence of Helicobacter pylori infection is decreasing in developed countries. In this study we included 22,612 patients in whom a first culture of gastric biopsy (routinely performed in our medical centres) yielded an interpretable result over a 20-year period (1988-2007) in Brussels. The effects of patients' age, gender and ethnic background were analysed. The overall proportion of H. pylori-infected patients was 37·7%, with a progressive decline over time (P<10(-5)). A gender effect was observed in adults. The lowest infection rate was observed in Western European patients (n=11,238) with respectively 36·2% and 15·2% infected subjects in 1988 and 2007, compared to 71·7% and 40% in North African patients (n=3200) (P<10(-5)). However, no trend of decline was observed over time in North African children aged ≤9 years. These data show the effects of time, age and ethnicity on the prevalence of H. pylori infection, and its complex heterogeneity in the same cosmopolitan urban area.
Asunto(s)
Infecciones por Helicobacter/epidemiología , Helicobacter pylori/aislamiento & purificación , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Bélgica/epidemiología , Biopsia , Niño , Preescolar , Estudios de Cohortes , Emigración e Inmigración , Etnicidad , Femenino , Mucosa Gástrica/microbiología , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Adulto JovenRESUMEN
The Authors describe a case of presacral hemorrhage after a colonoscopy in a patient taking anticoagulation. Surgical treatment was necessary to stop the hemorrhage.
Asunto(s)
Enfermedades del Colon/etiología , Colonoscopía/efectos adversos , Hemorragia Gastrointestinal/etiología , Perforación Intestinal/etiología , Anciano , Enfermedad Crónica , Enfermedades del Colon/diagnóstico por imagen , Colonoscopía/métodos , Estreñimiento/diagnóstico , Drenaje/métodos , Femenino , Estudios de Seguimiento , Hemorragia Gastrointestinal/diagnóstico por imagen , Humanos , Perforación Intestinal/cirugía , Laparotomía/métodos , Enfermedades Raras , Medición de Riesgo , Sacro , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
Cutaneous Paget's disease (PD) is a rare entity, predominantly involving the breasts. Anal involvement is rather exceptional, and can be associated with underlying malignancies, among which prostate and rectal adenocarcinoma. We report the case of a 71-year-old man suffering from a long history of anal itching, associated with an erythematosquamous lesion of the right buttock extending up to the anus. The diagnosis of perianal PD (PAPD) was confirmed by histopathological demonstration of Paget's cells from a biopsy performed after ineffective topical treatment. Radiological and further clinical inspections allowed us to exclude any synchronous malignancy. A first-step surgery consisted in coelioscopic diverting sigmoid colostomy, along with multiple perianal, anal and rectal biopsies revealing an anal canal involvement. Coelioscopic abdominoperineal surgery and a wide cutaneous excision were then performed. Histopathological analysis revealed positive posterior margin, requiring further excision. No adjuvant therapy was prescribed, and to this day, after a one-year and a half follow-up, the patient remains disease-free. Our case report and review of PAPD stress that appropriate management is required to improve the poor prognosis of this rare affection.
Asunto(s)
Neoplasias del Ano/patología , Enfermedad de Paget Extramamaria/patología , Anciano , Neoplasias del Ano/cirugía , Humanos , Masculino , Enfermedad de Paget Extramamaria/cirugía , Resultado del TratamientoRESUMEN
The article gives an overview of the current status of treatment of AP. The different therapeutical strategies are described and compared. The basic treatment for severe AP remains a medical therapy in an Intensive Care Unit. Surgical therapy is indicated in case of infection of necrotizing areas or other severe complications. The potential benefit of antiprotase agents and other new molecules is discussed.
Asunto(s)
Pancreatitis/terapia , Enfermedad Aguda , Antibacterianos/uso terapéutico , Aprotinina/uso terapéutico , Cuidados Críticos/métodos , Citocinas/antagonistas & inhibidores , Citocinas/inmunología , Drenaje , Nutrición Enteral/métodos , Humanos , Necrosis , Dolor/etiología , Pancreatectomía , Pancreatitis/complicaciones , Pancreatitis/diagnóstico , Pancreatitis/inmunología , Selección de Paciente , Pronóstico , Inhibidores de Serina Proteinasa/uso terapéutico , Índice de Severidad de la Enfermedad , Esfinterotomía Transduodenal , Resultado del TratamientoRESUMEN
Acute pancreatitis is an unusual complication of systemic lupus erythematosus but can also stem from immunosuppressive therapy. Although abnormal liver tests are commonly seen in SLE, peliosis hepatis is very rarely described. We report here the first case of SLE associating a severe acute pancreatitis with peliosis hepatis who responded well to the immunosuppressive therapy. As suggested by the favourable outcome in this case, the presence of peliosis hepatis in SLE cannot not be held as a strong argument against an aggressive immunosuppressive therapy.
Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Pancreatitis/etiología , Peliosis Hepática/etiología , Enfermedad Aguda , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la EnfermedadRESUMEN
Numerous epidemiological studies have shown the two main risk factors for Helicobacter pylori acquisition: childhood and low socio-economic level both in developing and developed countries. Nevertheless, in the absence of ubiquitous extra-human reservoir(s), the route(s) for person-to-person transmission remains undetermined. Very recent data favour the oro-oral route: besides gastric mucosa, mouth might be a sanctuary site and the oro-oral transmission hypothesis seems applicable worldwide. Nevertheless, the gastro-oral route (vomiting, gastro-oesophageal reflux) is still possible and deserves further research. In developing countries, feco-oral transmission (perhaps through the water supply) might be a significant mechanism of human contamination both for primary infection in children and perhaps, reinfection in adults.
Asunto(s)
Infecciones por Helicobacter/transmisión , Helicobacter pylori , Adulto , Factores de Edad , Niño , Reservorios de Enfermedades , Infecciones por Helicobacter/epidemiología , Humanos , Factores de Riesgo , Factores SocioeconómicosRESUMEN
A putative pathogenetic role has been ascribed to Helicobacter pylori in several extradigestive diseases, including vascular (atherosclerosis and ischaemic heart disease, primary Raynaud phenomenon, primary headache), autoimmune (Sjögren's syndrome, Henoch-Schönlein purpura, autoimmune thyroiditis, idiopathic arrythmias, Parkinson's disease, nonarterial anterior optic ischemic neuropathy), and skin diseases (chronic idiopathic urticaria, rosacea, alopecia areata), sideropenic anemia, growth retardation, late menarche, extragastric MALT lymphoma, diabetes mellitus, hepatic encephalopathy, sudden infant death syndrome, and anorexia of aging. We examine critically the strength of the evidence linking these diseases to Helicobacter pylori, using ischaemic heart disease as an example of epidemiological techniques, and skin diseases as an example of treatment studies. By the standards of evidence-based medicine, studies have been often of low quality. The best evidence usually is not indicative of a role for Helicobacter pylori in these diseases.
Asunto(s)
Medicina Basada en la Evidencia , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Isquemia Miocárdica/microbiología , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/patogenicidad , Humanos , Enfermedades Cutáneas Bacterianas/microbiologíaRESUMEN
"HP testing must be regarded as ONE of the important elements of the proper diagnostic work-up of a DISEASE, managed in close cooperation between GP's and specialists": that's the key message of the national consensus meeting held in CHU Brugmann on February 6th and 7th 1998. HP testing (usually by 2 direct methods: RUT-histology) and eradication treatment (ER), in infected patients, are strongly recommended in: 1. Past or current GDU (absolute indication), regardless of activity, complication(s), NSAID intake; 2. Low-grade MALT Lymphomas (Stage IE1) unequivocally diagnosed, managed and followed-up in specialised centers; 3. Post endoscopic resection of EGC. ER is advisable in HP carriers with a family history of gastric cancer. Chronic atrophic-, lymphocytic-, giant folds gastritis and hyperplastic polyps are acceptable indications for ER as well as scheduled long-term NSAID treatment in individuals with known HP status. Systematic ER in HP+ patients with fully investigated NUD is not indicated but could be considered in individual patients. Extra alimentary disorders and auto immune gastritis are no indication and there was no consensus for a "test and treat" policy in patients under 45 yrs old without alarm symptoms. Systematic screening of asymptomatic individuals is not recommended. A correct monitoring of eradication after treatment is recommended, mainly by UBT. In severe or refractory PUD, symptom recurrence and follow-up of EGC and Maltomas, endoscopic follow-up with HP testing is mandatory. The recommended first line treatment course (except known allergy or intolerance) is PPI full dose bid, Clarithromycin 500 mg bid Amoxycillin 1000 mg bid (7 days minimal 10 days maximal). RBC-based schemes must be locally validated and quadruple therapy is proposed when retreatment is needed. Culture, optional after the first treatment failure, is strongly recommended after a second failure. Overall, ER therapies are safe and neither the decreased efficacy of acid-lowering drugs, nor the possible increased risk of peptic oesophagitis are considered as contra-indications to eradicate. ER is cost-effective and cost-beneficial in PUD and adjusted number of pills delivered would cut costs. No clear economic data are currently available for a potential benefit of ER in GC prevention or NUD management. A national monitoring of HP resistance (Macrolides and Imidazoles) must be organized by specialised centers.
Asunto(s)
Enfermedades Gastrointestinales/microbiología , Enfermedades Gastrointestinales/terapia , Infecciones por Helicobacter/terapia , Helicobacter pylori/aislamiento & purificación , Infecciones por Helicobacter/diagnóstico , HumanosRESUMEN
HP infection of the stomach is not a risk factor for reflux oesophagitis, and may even protect against reflux oesophagitis. HP eradication may lead to an accelerated development of GERD in duodenal ulcer disease patients. It is unknown whether this is also true for HP positive patients who do not suffer from duodenal ulcer disease. HP eradication may decrease the efficacy of acid secretion lowering drugs such as Proton Pump Inhibitors and H2-Receptor Antagonists. It is unclear whether this has any practical consequences, but it cannot be excluded that some patient may need an increased dose of acid secretion lowering drugs after HP eradication for control of symptoms and lesions of GERD. There are conflicting data on the possibility that long-term proton pump inhibitor treatment may accelerate the development of atrophic gastritis in Helicobacter pylori positive patients. The possible acceleration of atrophic gastritis development in HP positive patients using strong acid secretion inhibitors is the strongest argument in favour of eradicating HP in patients receiving long term potent acid inhibition, especially GERD patients. In view of the uncertainty concerning these data, both eradicating and non eradicating HP in patients with GERD can be defended.
Asunto(s)
Gastritis/complicaciones , Reflujo Gastroesofágico/prevención & control , Infecciones por Helicobacter/complicaciones , Helicobacter pylori/aislamiento & purificación , Antiulcerosos/uso terapéutico , Ensayos Clínicos Controlados como Asunto , Gastritis/tratamiento farmacológico , Gastritis/microbiología , Reflujo Gastroesofágico/complicaciones , Reflujo Gastroesofágico/microbiología , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/tratamiento farmacológico , Humanos , Pronóstico , Inhibidores de la Bomba de Protones , Bombas de Protones/efectos adversos , Bombas de Protones/uso terapéutico , Factores de RiesgoAsunto(s)
Antibacterianos , Antiulcerosos/uso terapéutico , Quimioterapia Combinada/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Inhibidores de la Bomba de Protones , Ensayos Clínicos como Asunto , Humanos , Pronóstico , Bombas de Protones/uso terapéutico , Resultado del TratamientoAsunto(s)
Antiulcerosos/economía , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/aislamiento & purificación , Úlcera Gástrica/tratamiento farmacológico , Antiulcerosos/uso terapéutico , Costo de Enfermedad , Costos y Análisis de Costo , Economía Farmacéutica/estadística & datos numéricos , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/economía , Humanos , Modelos Económicos , Omeprazol/economía , Omeprazol/uso terapéutico , Ranitidina/economía , Ranitidina/uso terapéutico , Neoplasias Gástricas/etiología , Neoplasias Gástricas/prevención & control , Úlcera Gástrica/economía , Úlcera Gástrica/microbiologíaRESUMEN
Currently, the first therapeutic attempt to eradicate Helicobacter pylori fails in one case out of six in intention to treat analysis. The main causes of failure are bad compliance, partly because of side effects that are severe in 1 to 4% of cases, absence of local validation of the treatment scheme, since some differences do exist between regions and countries, primary and secondary resistance of the strain (stable for Imidazole-derivates, but increasing for Macrolides), and, to a lesser extent, smoking and pre-treatment with proton pump inhibitors. Moreover, in routine medicine, inappropriate treatment cocktails are still prescribed, even by gastroenterologists. Obviously, there is a need for careful medical education and information both as far as concerns doctors and patients, for well-designed prescription, based on local experience and the precise previous history of every patient, as well as for continuous monitoring of the bacterial resistance to antibiotics. Culture of the strain is recommended after eradication failure with the classic one-week triple therapy, but if reliable culture and resistance testing are not available, the quadruple therapy as a second-line treatment is, so far, the best choice.
Asunto(s)
Antibacterianos , Antiulcerosos/uso terapéutico , Quimioterapia Combinada/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Recuento de Colonia Microbiana , Farmacorresistencia Microbiana , Estudios de Seguimiento , Helicobacter pylori/crecimiento & desarrollo , Humanos , Pronóstico , Inhibidores de la Bomba de Protones , Reproducibilidad de los Resultados , Insuficiencia del TratamientoRESUMEN
BACKGROUND: Ranitidine bismuth citrate is a novel salt of ranitidine and a bismuth citrate complex. It has intrinsic antisecretory and anti-Helicobacter pylori activity, but monotherapy rarely eradicates H. pylori infection in man. AIM: A pilot study to investigate rates of H. pylori eradication achieved by co-prescription of ranitidine bismuth citrate with antibiotics, and to identify several regimens which would merit further investigation. METHOD: One hundred dyspeptic patients infected with H. pylori were randomly allocated to treatment with ranitidine bismuth citrate 800 mg b.d. plus either amoxycillin, metronidazole, clarithromycin, cefuroxime axetil, tetracycline, tetracycline plus metronidazole or clarithromycin plus tetracycline for 14 days. Eradication of infection was assessed using the 13C-urea breath test 4 weeks after the end of treatment. RESULTS: In a per protocol analysis eradication of H. pylori ranged between 22 and 100%; the intention-to-treat eradication rates ranged between 15 and 92%. No adverse events were specifically attributed to ranitidine bismuth citrate. CONCLUSION: Co-prescription therapy, using ranitidine bismuth citrate and one or more antibiotics, is suitable for further investigation in large-scale clinical trials in patients infected with H. pylori.
Asunto(s)
Antibacterianos/uso terapéutico , Bismuto/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Ranitidina/análogos & derivados , Adulto , Anciano , Antibacterianos/administración & dosificación , Bismuto/administración & dosificación , Bismuto/sangre , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ranitidina/administración & dosificación , Ranitidina/uso terapéuticoRESUMEN
After a decade of research, Helicobacter pylori eradication is still a problem because of the steady increase of bacterial resistance (imidazole, macrolides), pH-dependent efficiency of antibiotics, poor compliance of patients and frequent side effects of the therapies. After the failure of various monotherapies and the unefficiency of Amoxicillin-Imidazole combination for Imidazole-resistant strains, the two weeks ¿Oral Triple Therapy' with a 85% mean eradication rate, was abandoned because of a mean 35% side effects rate. The current goal is to obtain 90% eradication rate and the excellent results of german studies with a 2 weeks regimen combining a Proton Pump Inhibitor (PPI) with Amoxicillin have not been confirmed elsewhere in Europe. PPI plus Clarithromycin (two weeks) gave a mean 72% eradication rate on an ITT basis. The short, low-dose combination PPI-Clarithromycin-Imidazole for one week proposed by Bazzoli is very efficient in a population where Imidazole resistant strains are rare. The recent result of one week with (Omeprazole 20-Clarithromycin 250-Tinidazole 500) BID or (Omeprazole 20-Clarithromycin 500-Amoxi 1000) BID reached a 95% eradication rate but these very promising results are not confirmed in Belgium in an on-going study including 147 patients.